Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Brain Stem Neoplasms | 16 | 2020 | 204 | 4.040 |
Why?
|
Brain Neoplasms | 43 | 2024 | 8860 | 2.770 |
Why?
|
Glioma | 25 | 2024 | 3401 | 2.440 |
Why?
|
Magnetic Resonance Imaging | 74 | 2023 | 35423 | 1.430 |
Why?
|
Fluorodeoxyglucose F18 | 5 | 2017 | 2017 | 1.210 |
Why?
|
Neurofibromatosis 1 | 7 | 2022 | 568 | 1.030 |
Why?
|
Positron-Emission Tomography | 9 | 2018 | 6274 | 0.980 |
Why?
|
Diagnostic Imaging | 11 | 2023 | 3508 | 0.970 |
Why?
|
Medulloblastoma | 9 | 2022 | 683 | 0.870 |
Why?
|
Central Nervous System Neoplasms | 9 | 2022 | 895 | 0.860 |
Why?
|
Child | 105 | 2024 | 77679 | 0.850 |
Why?
|
Phantoms, Imaging | 5 | 2018 | 2480 | 0.790 |
Why?
|
Infratentorial Neoplasms | 4 | 2021 | 94 | 0.680 |
Why?
|
Child, Preschool | 71 | 2022 | 40992 | 0.640 |
Why?
|
Magnetic Resonance Spectroscopy | 11 | 2019 | 3760 | 0.630 |
Why?
|
Cerebellar Neoplasms | 6 | 2022 | 587 | 0.620 |
Why?
|
Cerebral Ventricles | 8 | 2012 | 544 | 0.600 |
Why?
|
Image Interpretation, Computer-Assisted | 5 | 2020 | 3328 | 0.580 |
Why?
|
Nuclear Medicine | 1 | 2018 | 233 | 0.530 |
Why?
|
Neuroradiography | 1 | 2015 | 70 | 0.530 |
Why?
|
Brain Stem | 3 | 2019 | 845 | 0.490 |
Why?
|
Ependymoma | 4 | 2022 | 334 | 0.480 |
Why?
|
Central Nervous System Diseases | 2 | 2015 | 518 | 0.440 |
Why?
|
Astrocytoma | 4 | 2008 | 789 | 0.440 |
Why?
|
Neurology | 3 | 2018 | 764 | 0.430 |
Why?
|
Radiopharmaceuticals | 2 | 2014 | 2662 | 0.430 |
Why?
|
Diffusion Magnetic Resonance Imaging | 5 | 2022 | 2737 | 0.420 |
Why?
|
Adolescent | 68 | 2023 | 85759 | 0.410 |
Why?
|
Tomography, X-Ray Computed | 15 | 2019 | 20123 | 0.410 |
Why?
|
Surface Plasmon Resonance | 2 | 2022 | 274 | 0.410 |
Why?
|
Infant | 44 | 2020 | 35129 | 0.400 |
Why?
|
Headache | 1 | 2019 | 1226 | 0.390 |
Why?
|
Neurofibroma, Plexiform | 3 | 2013 | 71 | 0.380 |
Why?
|
Brain | 21 | 2022 | 26413 | 0.380 |
Why?
|
Research Report | 1 | 2013 | 355 | 0.360 |
Why?
|
Benzimidazoles | 4 | 2022 | 851 | 0.330 |
Why?
|
Humans | 141 | 2024 | 744220 | 0.330 |
Why?
|
Societies, Medical | 2 | 2018 | 3741 | 0.320 |
Why?
|
Meningeal Neoplasms | 5 | 2018 | 1241 | 0.320 |
Why?
|
Organizations | 1 | 2008 | 170 | 0.290 |
Why?
|
Clinical Trials as Topic | 3 | 2018 | 7908 | 0.290 |
Why?
|
Image Processing, Computer-Assisted | 6 | 2023 | 8950 | 0.290 |
Why?
|
Quinolones | 4 | 2011 | 367 | 0.290 |
Why?
|
Pediatrics | 3 | 2015 | 3469 | 0.290 |
Why?
|
Spinal Cord Diseases | 1 | 2009 | 299 | 0.280 |
Why?
|
Neuroectodermal Tumors | 1 | 2006 | 27 | 0.280 |
Why?
|
Male | 83 | 2024 | 350027 | 0.270 |
Why?
|
Radiation Injuries | 3 | 2019 | 1178 | 0.270 |
Why?
|
Multicenter Studies as Topic | 2 | 2010 | 1677 | 0.270 |
Why?
|
Spinal Cord Neoplasms | 3 | 2022 | 281 | 0.270 |
Why?
|
Hypothalamic Neoplasms | 3 | 2005 | 22 | 0.270 |
Why?
|
Female | 87 | 2024 | 380197 | 0.260 |
Why?
|
Back Pain | 1 | 2009 | 545 | 0.260 |
Why?
|
Quinazolines | 4 | 2015 | 1356 | 0.260 |
Why?
|
Spinal Diseases | 2 | 2009 | 538 | 0.260 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 8 | 2021 | 11493 | 0.250 |
Why?
|
Contrast Media | 2 | 2016 | 5300 | 0.250 |
Why?
|
Retrospective Studies | 29 | 2024 | 77426 | 0.250 |
Why?
|
Image Enhancement | 1 | 2015 | 2921 | 0.240 |
Why?
|
Chromosomes, Human, Pair 22 | 1 | 2005 | 351 | 0.240 |
Why?
|
Magnetic Resonance Angiography | 3 | 2006 | 1442 | 0.240 |
Why?
|
Neurofibromin 2 | 1 | 2005 | 267 | 0.240 |
Why?
|
Temporal Muscle | 1 | 2023 | 37 | 0.230 |
Why?
|
Permeability | 2 | 2018 | 738 | 0.230 |
Why?
|
Antineoplastic Agents | 12 | 2021 | 13668 | 0.230 |
Why?
|
Growth Charts | 1 | 2023 | 61 | 0.230 |
Why?
|
Diencephalon | 2 | 2005 | 56 | 0.220 |
Why?
|
Disease-Free Survival | 7 | 2017 | 6893 | 0.220 |
Why?
|
Loss of Heterozygosity | 1 | 2005 | 684 | 0.220 |
Why?
|
Scoliosis | 4 | 2003 | 725 | 0.210 |
Why?
|
Diffusion | 2 | 2017 | 833 | 0.210 |
Why?
|
Heredodegenerative Disorders, Nervous System | 1 | 2002 | 17 | 0.210 |
Why?
|
Developmental Disabilities | 2 | 2010 | 1456 | 0.210 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 3 | 2002 | 1107 | 0.210 |
Why?
|
Failure to Thrive | 2 | 2005 | 136 | 0.210 |
Why?
|
Imaging, Three-Dimensional | 3 | 2013 | 4044 | 0.200 |
Why?
|
Brain Diseases, Metabolic | 1 | 2002 | 42 | 0.200 |
Why?
|
Optic Nerve Glioma | 1 | 2021 | 32 | 0.200 |
Why?
|
Guillain-Barre Syndrome | 1 | 2023 | 123 | 0.200 |
Why?
|
Nervous System Diseases | 2 | 2023 | 1623 | 0.200 |
Why?
|
Histones | 2 | 2023 | 2600 | 0.200 |
Why?
|
Connective Tissue Diseases | 1 | 2023 | 264 | 0.190 |
Why?
|
Meningioma | 2 | 2009 | 1209 | 0.180 |
Why?
|
Disease Progression | 8 | 2023 | 13280 | 0.180 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2016 | 9230 | 0.180 |
Why?
|
Prenatal Diagnosis | 4 | 2011 | 1236 | 0.180 |
Why?
|
Contractile Proteins | 1 | 2000 | 246 | 0.170 |
Why?
|
Infant, Newborn | 18 | 2015 | 25618 | 0.170 |
Why?
|
Systemic Inflammatory Response Syndrome | 2 | 2023 | 611 | 0.170 |
Why?
|
Cranial Nerve Neoplasms | 2 | 1997 | 129 | 0.170 |
Why?
|
Molecular Biology | 1 | 2023 | 596 | 0.170 |
Why?
|
Combined Modality Therapy | 9 | 2021 | 8628 | 0.170 |
Why?
|
Ultrasonography, Prenatal | 6 | 2012 | 1695 | 0.170 |
Why?
|
Choristoma | 1 | 2000 | 213 | 0.170 |
Why?
|
Tectum Mesencephali | 1 | 1998 | 20 | 0.160 |
Why?
|
Guanine | 2 | 2011 | 274 | 0.160 |
Why?
|
Perfusion Imaging | 1 | 2020 | 195 | 0.160 |
Why?
|
Photons | 2 | 2019 | 588 | 0.160 |
Why?
|
Hydrocephalus | 4 | 2011 | 748 | 0.160 |
Why?
|
Prognosis | 10 | 2021 | 29050 | 0.160 |
Why?
|
Craniopharyngioma | 1 | 2020 | 281 | 0.150 |
Why?
|
Craniocerebral Trauma | 1 | 2002 | 482 | 0.150 |
Why?
|
Brain Diseases | 1 | 2007 | 1564 | 0.150 |
Why?
|
Neurosecretory Systems | 1 | 1999 | 231 | 0.150 |
Why?
|
Optic Chiasm | 1 | 1997 | 87 | 0.150 |
Why?
|
Endpoint Determination | 1 | 2020 | 601 | 0.150 |
Why?
|
Radiation Oncology | 1 | 2023 | 555 | 0.140 |
Why?
|
Polyethylene Glycols | 2 | 2020 | 1181 | 0.140 |
Why?
|
Dacarbazine | 2 | 2011 | 567 | 0.140 |
Why?
|
Endocrine System Diseases | 1 | 1999 | 248 | 0.140 |
Why?
|
Angiogenesis Inhibitors | 4 | 2013 | 2038 | 0.140 |
Why?
|
Interferon-alpha | 1 | 2020 | 895 | 0.140 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2024 | 2041 | 0.130 |
Why?
|
Phenylketonurias | 1 | 1996 | 122 | 0.130 |
Why?
|
Microfilament Proteins | 1 | 2000 | 1152 | 0.130 |
Why?
|
Pons | 2 | 2019 | 245 | 0.130 |
Why?
|
Pituitary Neoplasms | 3 | 2020 | 1346 | 0.130 |
Why?
|
Piperazines | 2 | 2021 | 2491 | 0.130 |
Why?
|
Indoles | 2 | 2016 | 1838 | 0.120 |
Why?
|
Radiography | 8 | 2023 | 7022 | 0.120 |
Why?
|
Anus, Imperforate | 1 | 1994 | 66 | 0.120 |
Why?
|
Niacinamide | 1 | 2016 | 416 | 0.120 |
Why?
|
Fetal Diseases | 2 | 2011 | 903 | 0.120 |
Why?
|
Ice | 1 | 2014 | 104 | 0.120 |
Why?
|
Radiotherapy Dosage | 4 | 2019 | 2878 | 0.120 |
Why?
|
Orbital Diseases | 1 | 1996 | 181 | 0.120 |
Why?
|
Neoplasms, Nerve Tissue | 1 | 2013 | 23 | 0.120 |
Why?
|
Orbital Neoplasms | 1 | 1996 | 225 | 0.110 |
Why?
|
Camptothecin | 2 | 2013 | 576 | 0.110 |
Why?
|
Clinical Trials, Phase I as Topic | 3 | 2011 | 323 | 0.110 |
Why?
|
Benchmarking | 1 | 2020 | 1042 | 0.110 |
Why?
|
Hypoxia, Brain | 1 | 2014 | 133 | 0.110 |
Why?
|
Protein Kinase Inhibitors | 3 | 2021 | 5529 | 0.110 |
Why?
|
Gene Deletion | 2 | 2006 | 2751 | 0.110 |
Why?
|
Neural Tube Defects | 1 | 1994 | 256 | 0.110 |
Why?
|
Treatment Outcome | 17 | 2021 | 63119 | 0.110 |
Why?
|
Maximum Tolerated Dose | 6 | 2011 | 892 | 0.110 |
Why?
|
Cranial Irradiation | 1 | 1995 | 401 | 0.100 |
Why?
|
Radionuclide Imaging | 3 | 2013 | 2030 | 0.100 |
Why?
|
Microcephaly | 1 | 1996 | 432 | 0.100 |
Why?
|
ROC Curve | 3 | 2018 | 3527 | 0.100 |
Why?
|
Survival Analysis | 4 | 2020 | 10250 | 0.100 |
Why?
|
Urogenital Abnormalities | 1 | 1994 | 261 | 0.100 |
Why?
|
Survival Rate | 6 | 2013 | 12781 | 0.100 |
Why?
|
Visual Pathways | 1 | 1996 | 565 | 0.100 |
Why?
|
DNA Mutational Analysis | 1 | 2020 | 4188 | 0.100 |
Why?
|
Telomerase | 1 | 2016 | 729 | 0.100 |
Why?
|
Septum Pellucidum | 1 | 2011 | 58 | 0.100 |
Why?
|
Neurofibromatoses | 2 | 2013 | 299 | 0.100 |
Why?
|
Adult | 33 | 2022 | 214035 | 0.090 |
Why?
|
Observer Variation | 7 | 2010 | 2593 | 0.090 |
Why?
|
Neurofibromatosis 2 | 1 | 2004 | 380 | 0.090 |
Why?
|
Thallium Radioisotopes | 2 | 2002 | 139 | 0.090 |
Why?
|
Aspartic Acid | 2 | 2004 | 576 | 0.090 |
Why?
|
Reproducibility of Results | 5 | 2014 | 19907 | 0.090 |
Why?
|
Antisickling Agents | 1 | 2010 | 80 | 0.090 |
Why?
|
Neuroma, Acoustic | 1 | 2013 | 451 | 0.090 |
Why?
|
Cerebral Arterial Diseases | 1 | 2010 | 82 | 0.090 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2023 | 288 | 0.090 |
Why?
|
Meningitis | 2 | 2006 | 216 | 0.090 |
Why?
|
Young Adult | 13 | 2021 | 56436 | 0.090 |
Why?
|
Pregnancy Outcome | 4 | 2012 | 2796 | 0.090 |
Why?
|
Angiomatosis | 1 | 2009 | 49 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 3 | 2015 | 6535 | 0.080 |
Why?
|
Pyridines | 1 | 2021 | 2822 | 0.080 |
Why?
|
Radiology | 1 | 2023 | 2099 | 0.080 |
Why?
|
Neuroectodermal Tumors, Primitive | 2 | 2006 | 140 | 0.080 |
Why?
|
Mutation | 3 | 2023 | 29784 | 0.080 |
Why?
|
Hydroxyurea | 1 | 2010 | 290 | 0.080 |
Why?
|
Vision Disorders | 1 | 1996 | 1059 | 0.080 |
Why?
|
Snake Venoms | 1 | 2008 | 39 | 0.080 |
Why?
|
Water | 1 | 2014 | 1395 | 0.080 |
Why?
|
Follow-Up Studies | 12 | 2017 | 39045 | 0.080 |
Why?
|
Medulla Oblongata | 1 | 1999 | 243 | 0.080 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2010 | 628 | 0.080 |
Why?
|
Head and Neck Neoplasms | 1 | 2002 | 2732 | 0.080 |
Why?
|
Corpus Callosum | 2 | 2006 | 737 | 0.080 |
Why?
|
Algorithms | 4 | 2020 | 13885 | 0.070 |
Why?
|
Prospective Studies | 10 | 2022 | 53280 | 0.070 |
Why?
|
Monitoring, Intraoperative | 1 | 2014 | 953 | 0.070 |
Why?
|
Hemorrhage | 2 | 2013 | 3461 | 0.070 |
Why?
|
Anisotropy | 1 | 2010 | 1265 | 0.070 |
Why?
|
Minority Groups | 1 | 2014 | 1223 | 0.070 |
Why?
|
Palate, Soft | 1 | 2006 | 96 | 0.070 |
Why?
|
Perioperative Care | 1 | 2014 | 1000 | 0.070 |
Why?
|
Radiotherapy | 2 | 2010 | 1525 | 0.070 |
Why?
|
Hydrazines | 1 | 2008 | 226 | 0.070 |
Why?
|
Forecasting | 1 | 2015 | 2949 | 0.070 |
Why?
|
Diagnosis, Differential | 3 | 2015 | 12961 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2002 | 4033 | 0.070 |
Why?
|
Emaciation | 1 | 2005 | 5 | 0.070 |
Why?
|
Adenoma | 1 | 1996 | 2174 | 0.070 |
Why?
|
United States | 8 | 2023 | 69867 | 0.070 |
Why?
|
Brain Damage, Chronic | 2 | 1997 | 265 | 0.070 |
Why?
|
Mothers | 1 | 1996 | 2165 | 0.070 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 664 | 0.070 |
Why?
|
Supratentorial Neoplasms | 1 | 2006 | 160 | 0.070 |
Why?
|
Busulfan | 1 | 2006 | 262 | 0.060 |
Why?
|
Sensitivity and Specificity | 4 | 2016 | 14726 | 0.060 |
Why?
|
Tumor Burden | 2 | 2022 | 1914 | 0.060 |
Why?
|
Organoplatinum Compounds | 1 | 2006 | 408 | 0.060 |
Why?
|
Central Nervous System | 2 | 2022 | 1357 | 0.060 |
Why?
|
Predictive Value of Tests | 5 | 2020 | 15070 | 0.060 |
Why?
|
Nerve Fibers, Myelinated | 1 | 2010 | 960 | 0.060 |
Why?
|
Rhabdoid Tumor | 1 | 2006 | 212 | 0.060 |
Why?
|
Collateral Circulation | 2 | 1997 | 287 | 0.060 |
Why?
|
Necrosis | 2 | 2019 | 1643 | 0.060 |
Why?
|
Chromosomes, Human, X | 1 | 2006 | 296 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2016 | 3591 | 0.060 |
Why?
|
Craniofacial Abnormalities | 1 | 2006 | 315 | 0.060 |
Why?
|
Neoplasms | 2 | 2023 | 21672 | 0.060 |
Why?
|
Smith-Lemli-Opitz Syndrome | 1 | 2003 | 46 | 0.060 |
Why?
|
Teratoma | 1 | 2006 | 387 | 0.060 |
Why?
|
Brain Abscess | 2 | 1995 | 118 | 0.060 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 1996 | 2408 | 0.060 |
Why?
|
Metabolism, Inborn Errors | 1 | 2006 | 288 | 0.060 |
Why?
|
Cerebral Hemorrhage | 1 | 1995 | 2647 | 0.060 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2007 | 780 | 0.060 |
Why?
|
Utah | 1 | 2023 | 126 | 0.060 |
Why?
|
Endarterectomy | 1 | 1993 | 195 | 0.060 |
Why?
|
Cerebral Hemorrhage, Traumatic | 1 | 2002 | 20 | 0.050 |
Why?
|
Analysis of Variance | 4 | 2011 | 6367 | 0.050 |
Why?
|
Pyrroles | 1 | 2009 | 1143 | 0.050 |
Why?
|
Asphyxia Neonatorum | 1 | 2002 | 107 | 0.050 |
Why?
|
Quality of Life | 1 | 2023 | 12805 | 0.050 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2006 | 627 | 0.050 |
Why?
|
Anemia, Sickle Cell | 1 | 2010 | 1018 | 0.050 |
Why?
|
Proportional Hazards Models | 3 | 2011 | 12355 | 0.050 |
Why?
|
Gestational Age | 4 | 2011 | 3493 | 0.050 |
Why?
|
Leukodystrophy, Globoid Cell | 1 | 2001 | 32 | 0.050 |
Why?
|
Alzheimer Disease | 1 | 2022 | 8037 | 0.050 |
Why?
|
Ultrasonography, Doppler, Duplex | 1 | 2002 | 205 | 0.050 |
Why?
|
Thalidomide | 1 | 2006 | 890 | 0.050 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2005 | 601 | 0.050 |
Why?
|
Skull Fractures | 1 | 2002 | 195 | 0.050 |
Why?
|
Osteoblastoma | 1 | 2000 | 24 | 0.050 |
Why?
|
Cerebral Cortex | 3 | 2007 | 5709 | 0.050 |
Why?
|
Akinetic Mutism | 1 | 2000 | 11 | 0.050 |
Why?
|
Birth Injuries | 1 | 2002 | 148 | 0.050 |
Why?
|
Neoplasm Staging | 2 | 2021 | 11007 | 0.050 |
Why?
|
Diffusion Tensor Imaging | 1 | 2010 | 2305 | 0.050 |
Why?
|
Pelvis | 1 | 2004 | 729 | 0.050 |
Why?
|
Tantalum | 1 | 1990 | 56 | 0.050 |
Why?
|
Membrane Transport Proteins | 1 | 2006 | 1028 | 0.050 |
Why?
|
Stroke | 1 | 2023 | 9981 | 0.050 |
Why?
|
Human Growth Hormone | 1 | 2005 | 683 | 0.040 |
Why?
|
Spina Bifida Occulta | 1 | 1999 | 31 | 0.040 |
Why?
|
Pregnancy | 8 | 2012 | 29142 | 0.040 |
Why?
|
Hemostasis, Surgical | 1 | 1990 | 128 | 0.040 |
Why?
|
Postoperative Complications | 3 | 2014 | 15294 | 0.040 |
Why?
|
Scalp | 1 | 2002 | 380 | 0.040 |
Why?
|
Recurrence | 2 | 2008 | 8343 | 0.040 |
Why?
|
Fetus | 1 | 2006 | 1880 | 0.040 |
Why?
|
Orthopedic Fixation Devices | 1 | 1998 | 75 | 0.040 |
Why?
|
Regression Analysis | 2 | 2007 | 6461 | 0.040 |
Why?
|
Carotid Arteries | 1 | 1993 | 952 | 0.040 |
Why?
|
Intestinal Pseudo-Obstruction | 1 | 1998 | 48 | 0.040 |
Why?
|
Pseudarthrosis | 1 | 1998 | 59 | 0.040 |
Why?
|
Administration, Oral | 2 | 2017 | 3913 | 0.040 |
Why?
|
Abdomen | 1 | 2004 | 1118 | 0.040 |
Why?
|
Child Development | 1 | 2010 | 2223 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2021 | 322 | 0.040 |
Why?
|
Sulfonamides | 1 | 2008 | 1940 | 0.040 |
Why?
|
Spine | 2 | 2022 | 1145 | 0.040 |
Why?
|
Intelligence Tests | 1 | 1999 | 505 | 0.040 |
Why?
|
Quality Assurance, Health Care | 1 | 2008 | 2211 | 0.040 |
Why?
|
Pituitary Diseases | 1 | 1999 | 141 | 0.040 |
Why?
|
Hypothalamic Diseases | 1 | 1999 | 135 | 0.040 |
Why?
|
Neoplasm Seeding | 1 | 2018 | 87 | 0.040 |
Why?
|
Skull | 1 | 2002 | 813 | 0.040 |
Why?
|
Brain Edema | 1 | 2002 | 617 | 0.040 |
Why?
|
Purines | 1 | 2021 | 594 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2021 | 535 | 0.040 |
Why?
|
Amyloid | 1 | 2022 | 795 | 0.040 |
Why?
|
Lactic Acid | 1 | 2002 | 1132 | 0.040 |
Why?
|
Tablets | 1 | 2017 | 147 | 0.040 |
Why?
|
Linear Energy Transfer | 1 | 2018 | 154 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2015 | 10949 | 0.040 |
Why?
|
Hedgehog Proteins | 1 | 2022 | 783 | 0.040 |
Why?
|
Texas | 1 | 2018 | 392 | 0.040 |
Why?
|
Aminopyridines | 1 | 2021 | 542 | 0.040 |
Why?
|
Radiotherapy, Adjuvant | 2 | 1999 | 1770 | 0.040 |
Why?
|
Pia Mater | 1 | 1997 | 88 | 0.040 |
Why?
|
Cerebrospinal Fluid Shunts | 1 | 1998 | 189 | 0.040 |
Why?
|
Choline | 3 | 2004 | 493 | 0.040 |
Why?
|
Florida | 1 | 2018 | 435 | 0.040 |
Why?
|
Spinal Cord | 2 | 2022 | 1809 | 0.040 |
Why?
|
Statistics as Topic | 2 | 2015 | 2374 | 0.040 |
Why?
|
Enzyme Inhibitors | 1 | 2007 | 3800 | 0.040 |
Why?
|
Tissue Distribution | 2 | 2011 | 2335 | 0.040 |
Why?
|
Relative Biological Effectiveness | 1 | 2018 | 323 | 0.040 |
Why?
|
Retreatment | 1 | 1998 | 610 | 0.030 |
Why?
|
World Health Organization | 1 | 2022 | 1318 | 0.030 |
Why?
|
Syndrome | 2 | 2005 | 3250 | 0.030 |
Why?
|
Equipment Failure | 1 | 1998 | 579 | 0.030 |
Why?
|
Cerebral Angiography | 2 | 1997 | 1285 | 0.030 |
Why?
|
Prolactinoma | 1 | 1996 | 113 | 0.030 |
Why?
|
Physicians | 1 | 2014 | 4564 | 0.030 |
Why?
|
Pituitary Gland | 1 | 1999 | 665 | 0.030 |
Why?
|
Statistics, Nonparametric | 2 | 2012 | 2886 | 0.030 |
Why?
|
Blood Cell Count | 1 | 2016 | 402 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2018 | 402 | 0.030 |
Why?
|
Pneumothorax | 1 | 1998 | 379 | 0.030 |
Why?
|
Intestinal Obstruction | 1 | 1998 | 424 | 0.030 |
Why?
|
Research Design | 1 | 2011 | 5987 | 0.030 |
Why?
|
Mental Disorders | 1 | 1995 | 6601 | 0.030 |
Why?
|
Pyrimidines | 1 | 2007 | 2940 | 0.030 |
Why?
|
Likelihood Functions | 1 | 1998 | 1005 | 0.030 |
Why?
|
Biological Availability | 1 | 2015 | 396 | 0.030 |
Why?
|
Cloaca | 1 | 1994 | 52 | 0.030 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 1999 | 703 | 0.030 |
Why?
|
Phenylalanine | 1 | 1996 | 365 | 0.030 |
Why?
|
Brain Chemistry | 3 | 2004 | 982 | 0.030 |
Why?
|
Empyema, Subdural | 1 | 1994 | 12 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2021 | 956 | 0.030 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 1995 | 110 | 0.030 |
Why?
|
Epilepsy, Temporal Lobe | 1 | 1998 | 403 | 0.030 |
Why?
|
Moyamoya Disease | 1 | 1997 | 237 | 0.030 |
Why?
|
Feasibility Studies | 2 | 2019 | 5076 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 2 | 1999 | 3474 | 0.030 |
Why?
|
Cerebrovascular Circulation | 1 | 2004 | 2732 | 0.030 |
Why?
|
Meningoencephalitis | 1 | 1994 | 78 | 0.030 |
Why?
|
Alanine Transaminase | 1 | 2016 | 592 | 0.030 |
Why?
|
Spinal Neoplasms | 1 | 2000 | 760 | 0.030 |
Why?
|
Carotid Artery Diseases | 1 | 1990 | 882 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3270 | 0.030 |
Why?
|
Child Abuse | 1 | 2002 | 1030 | 0.030 |
Why?
|
Dandy-Walker Syndrome | 1 | 1993 | 43 | 0.030 |
Why?
|
Oligonucleotides | 1 | 2016 | 572 | 0.030 |
Why?
|
Uncertainty | 1 | 2018 | 734 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 1999 | 2649 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2013 | 4929 | 0.030 |
Why?
|
Pedigree | 1 | 2000 | 4648 | 0.030 |
Why?
|
Orbit | 1 | 1996 | 426 | 0.030 |
Why?
|
Neuroglia | 1 | 1998 | 927 | 0.030 |
Why?
|
Medical Records | 1 | 1998 | 1413 | 0.030 |
Why?
|
Arachnoid Cysts | 1 | 1993 | 59 | 0.030 |
Why?
|
Optic Nerve Diseases | 1 | 1996 | 328 | 0.030 |
Why?
|
Neurologic Examination | 1 | 1995 | 931 | 0.030 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2018 | 806 | 0.030 |
Why?
|
Time Factors | 3 | 2020 | 40063 | 0.020 |
Why?
|
Biomedical Research | 1 | 2007 | 3311 | 0.020 |
Why?
|
Suppositories | 1 | 1980 | 15 | 0.020 |
Why?
|
Glioblastoma | 1 | 2006 | 3481 | 0.020 |
Why?
|
Medical Oncology | 1 | 2023 | 2265 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2013 | 1420 | 0.020 |
Why?
|
Inpatients | 1 | 2023 | 2518 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2003 | 3611 | 0.020 |
Why?
|
Consensus | 1 | 2020 | 2958 | 0.020 |
Why?
|
DNA Modification Methylases | 1 | 2011 | 206 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2020 | 6612 | 0.020 |
Why?
|
Intracranial Aneurysm | 1 | 1990 | 1197 | 0.020 |
Why?
|
Proteinuria | 1 | 2013 | 657 | 0.020 |
Why?
|
Encephalitis | 1 | 1994 | 423 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 1799 | 0.020 |
Why?
|
Bone Diseases | 1 | 2004 | 416 | 0.020 |
Why?
|
Disease Management | 1 | 2021 | 2458 | 0.020 |
Why?
|
Drug Therapy, Combination | 2 | 2011 | 6485 | 0.020 |
Why?
|
DNA Repair Enzymes | 1 | 2011 | 349 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2011 | 644 | 0.020 |
Why?
|
Frontal Lobe | 1 | 1996 | 1407 | 0.020 |
Why?
|
Brain Ischemia | 1 | 1993 | 3265 | 0.020 |
Why?
|
Dilatation, Pathologic | 1 | 2010 | 520 | 0.020 |
Why?
|
Carcinogens | 1 | 1980 | 466 | 0.020 |
Why?
|
Critical Care | 1 | 2021 | 2644 | 0.020 |
Why?
|
Patient Discharge | 1 | 2021 | 3313 | 0.020 |
Why?
|
Lymphocytes | 1 | 2016 | 2617 | 0.020 |
Why?
|
Clostridium Infections | 1 | 1995 | 548 | 0.020 |
Why?
|
Age Factors | 2 | 2021 | 18367 | 0.020 |
Why?
|
Cerebral Arteries | 1 | 2010 | 494 | 0.020 |
Why?
|
Immunotherapy | 1 | 2023 | 4440 | 0.020 |
Why?
|
Aged | 6 | 2005 | 163253 | 0.020 |
Why?
|
Cerebrovascular Disorders | 1 | 2004 | 1504 | 0.020 |
Why?
|
Pneumonia | 1 | 1998 | 2134 | 0.020 |
Why?
|
Logistic Models | 3 | 2011 | 13409 | 0.020 |
Why?
|
Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2006 | 19 | 0.020 |
Why?
|
Hallucinations | 1 | 2009 | 360 | 0.020 |
Why?
|
Constriction, Pathologic | 1 | 2010 | 1107 | 0.020 |
Why?
|
Choroid Plexus Neoplasms | 1 | 2006 | 43 | 0.020 |
Why?
|
Fatigue | 1 | 2013 | 1531 | 0.020 |
Why?
|
Prevalence | 2 | 2011 | 15226 | 0.020 |
Why?
|
Blood Flow Velocity | 1 | 2010 | 1423 | 0.020 |
Why?
|
Cell Movement | 1 | 1998 | 5216 | 0.020 |
Why?
|
Cerebellum | 1 | 1993 | 1490 | 0.020 |
Why?
|
Injections, Spinal | 1 | 2006 | 303 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9275 | 0.020 |
Why?
|
Hyperkinesis | 1 | 2005 | 89 | 0.020 |
Why?
|
Massachusetts | 1 | 2018 | 8663 | 0.020 |
Why?
|
Nystagmus, Pathologic | 1 | 2005 | 96 | 0.020 |
Why?
|
Arthralgia | 1 | 2009 | 456 | 0.020 |
Why?
|
Cohort Studies | 2 | 2023 | 40559 | 0.020 |
Why?
|
Case-Control Studies | 3 | 1999 | 21752 | 0.010 |
Why?
|
Thioguanine | 1 | 2003 | 46 | 0.010 |
Why?
|
Drug Interactions | 1 | 2009 | 1458 | 0.010 |
Why?
|
Procarbazine | 1 | 2003 | 181 | 0.010 |
Why?
|
Lomustine | 1 | 2003 | 59 | 0.010 |
Why?
|
Hospitalization | 2 | 2021 | 10262 | 0.010 |
Why?
|
Neutrophils | 1 | 2016 | 3717 | 0.010 |
Why?
|
Area Under Curve | 1 | 2008 | 1655 | 0.010 |
Why?
|
Hydrogen | 1 | 2003 | 164 | 0.010 |
Why?
|
Middle Aged | 8 | 2005 | 213367 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2008 | 2272 | 0.010 |
Why?
|
Depressive Disorder | 1 | 1996 | 3750 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8387 | 0.010 |
Why?
|
Intraoperative Period | 1 | 1993 | 520 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 25043 | 0.010 |
Why?
|
Drug Evaluation | 1 | 2003 | 637 | 0.010 |
Why?
|
Vomiting | 1 | 2005 | 635 | 0.010 |
Why?
|
Acoustic Impedance Tests | 1 | 1982 | 109 | 0.010 |
Why?
|
Eye | 1 | 2006 | 729 | 0.010 |
Why?
|
Protons | 1 | 2007 | 1127 | 0.010 |
Why?
|
Tumor Microenvironment | 1 | 2013 | 3584 | 0.010 |
Why?
|
Vincristine | 1 | 2003 | 1036 | 0.010 |
Why?
|
Benzamides | 1 | 2007 | 1378 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2011 | 2848 | 0.010 |
Why?
|
Incidence | 1 | 2019 | 20945 | 0.010 |
Why?
|
Photomicrography | 1 | 2000 | 74 | 0.010 |
Why?
|
Gamma Cameras | 1 | 2000 | 36 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7281 | 0.010 |
Why?
|
Treatment Failure | 1 | 2006 | 2619 | 0.010 |
Why?
|
Carboplatin | 1 | 2003 | 800 | 0.010 |
Why?
|
Stainless Steel | 1 | 1990 | 80 | 0.010 |
Why?
|
Twins, Monozygotic | 1 | 2001 | 458 | 0.010 |
Why?
|
Movement | 1 | 2006 | 1471 | 0.010 |
Why?
|
Hematologic Diseases | 1 | 2003 | 498 | 0.010 |
Why?
|
Anticonvulsants | 1 | 2009 | 1917 | 0.010 |
Why?
|
Syringomyelia | 1 | 1999 | 64 | 0.010 |
Why?
|
Boston | 1 | 2011 | 9311 | 0.010 |
Why?
|
Bone Diseases, Developmental | 1 | 1999 | 130 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2005 | 1255 | 0.010 |
Why?
|
Lumbosacral Region | 1 | 1999 | 310 | 0.010 |
Why?
|
Nerve Compression Syndromes | 1 | 1999 | 161 | 0.010 |
Why?
|
Mice, Nude | 1 | 2004 | 3689 | 0.010 |
Why?
|
Celiac Disease | 1 | 2005 | 785 | 0.010 |
Why?
|
Hydrocortisone | 1 | 2005 | 1826 | 0.010 |
Why?
|
Insulin-Like Growth Factor I | 1 | 2005 | 2014 | 0.010 |
Why?
|
Spinal Dysraphism | 1 | 1999 | 161 | 0.010 |
Why?
|
Spinal Cord Compression | 1 | 1999 | 235 | 0.010 |
Why?
|
Magnetics | 1 | 1990 | 607 | 0.010 |
Why?
|
Ultrasonography | 1 | 2010 | 5982 | 0.010 |
Why?
|
Intraoperative Care | 1 | 2000 | 767 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 1981 | 4251 | 0.010 |
Why?
|
Electroencephalography | 2 | 1998 | 6150 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 1995 | 57768 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1997 | 1676 | 0.010 |
Why?
|
Phosphorylation | 1 | 2006 | 8437 | 0.010 |
Why?
|
Cholesterol | 1 | 2003 | 2911 | 0.010 |
Why?
|
Oxygen | 1 | 2006 | 4187 | 0.010 |
Why?
|
Metronidazole | 1 | 1995 | 217 | 0.010 |
Why?
|
Models, Structural | 1 | 1993 | 361 | 0.010 |
Why?
|
Gadolinium | 1 | 1998 | 952 | 0.010 |
Why?
|
Hypertension | 1 | 2013 | 8480 | 0.010 |
Why?
|
AIDS Dementia Complex | 1 | 1994 | 153 | 0.010 |
Why?
|
Genotype | 1 | 2008 | 12956 | 0.010 |
Why?
|
Cisterna Magna | 1 | 1993 | 41 | 0.010 |
Why?
|
Liver | 1 | 2009 | 7472 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2006 | 4465 | 0.010 |
Why?
|
Melanoma | 1 | 1981 | 5475 | 0.010 |
Why?
|
Penicillins | 1 | 1995 | 380 | 0.010 |
Why?
|
Postoperative Period | 1 | 1997 | 1841 | 0.010 |
Why?
|
Life Expectancy | 1 | 1998 | 1184 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1981 | 5670 | 0.010 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 1994 | 657 | 0.010 |
Why?
|
Risk Assessment | 1 | 2011 | 23337 | 0.010 |
Why?
|
Nevus, Pigmented | 1 | 1981 | 219 | 0.010 |
Why?
|
Models, Biological | 1 | 2005 | 9582 | 0.010 |
Why?
|
Phenotype | 1 | 2006 | 16365 | 0.000 |
Why?
|
Congenital Abnormalities | 1 | 1993 | 707 | 0.000 |
Why?
|
Severity of Illness Index | 1 | 2003 | 15538 | 0.000 |
Why?
|
Psychiatric Status Rating Scales | 1 | 1996 | 6037 | 0.000 |
Why?
|
Disease Models, Animal | 1 | 2004 | 18027 | 0.000 |
Why?
|
Immunity, Cellular | 1 | 1981 | 1607 | 0.000 |
Why?
|
Risk Factors | 1 | 2011 | 72280 | 0.000 |
Why?
|
Double-Blind Method | 1 | 1998 | 12035 | 0.000 |
Why?
|
Compliance | 1 | 1982 | 104 | 0.000 |
Why?
|
Air Pressure | 1 | 1982 | 75 | 0.000 |
Why?
|
Neoplasm Metastasis | 1 | 1981 | 4841 | 0.000 |
Why?
|
Ear Diseases | 1 | 1982 | 170 | 0.000 |
Why?
|
Otitis Media | 1 | 1982 | 277 | 0.000 |
Why?
|
Mice | 1 | 2004 | 81178 | 0.000 |
Why?
|
Animals | 2 | 2004 | 168788 | 0.000 |
Why?
|
Rats | 1 | 1980 | 24273 | 0.000 |
Why?
|